# Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune Diseases

> **NCT07558850** · NA · RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 72 (estimated)

## Conditions studied

- Rheumatoid Arthritis
- Dermatomyositis
- Systemic Lupus Erythematosus
- Systemic Sclerosis

## Interventions

- **BIOLOGICAL:** anti-CD19/BCMA-UCAR-T cells

## Key facts

- **NCT ID:** NCT07558850
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-10
- **Primary completion:** 2028-01-10
- **Final completion:** 2029-01-10
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2026-04-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07558850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07558850, "Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune Diseases". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07558850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*